Cargando…

Treating Nonalcoholic Fatty Liver Disease From the Outside In?

Detalles Bibliográficos
Autor principal:	Flynn, Charles R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477184/ https://www.ncbi.nlm.nih.gov/pubmed/30677403 http://dx.doi.org/10.1016/j.jcmgh.2018.12.008

Ejemplares similares

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Diabetes and Nonalcoholic Fatty Liver Disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012)

Diet and Lifestyle in Nonalcoholic Fatty Liver Disease
por: Martínez-Beamonte, Roberto, et al.
Publicado: (2020)

Implications of comorbidities in nonalcoholic fatty liver disease
por: Song, Sherlot Juan, et al.
Publicado: (2023)

Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
por: Alam, Shahinul, et al.
Publicado: (2021)

The utility of ezetimibe therapy in nonalcoholic fatty liver disease
por: Jun, Baek Gyu, et al.
Publicado: (2019)

Nonalcoholic Fatty Liver Disease: Its Mechanisms and Complications
por: El Ouaamari, Abdelfattah, et al.
Publicado: (2013)

Noninvasive Markers for the Diagnosis of Nonalcoholic Fatty Liver Disease
por: Kim, Sang Yong
Publicado: (2013)

Role of cenicriviroc in the management of nonalcoholic fatty liver disease
por: Neokosmidis, Georgios, et al.
Publicado: (2018)

Imaging methods in the assessment of nonalcoholic fatty liver disease
por: Parente, Daniella Braz
Publicado: (2020)

Update cognition of nonalcoholic fatty liver disease/metabolism‐associated fatty liver disease
por: Gu, Weijun, et al.
Publicado: (2022)

The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
por: Park, Ji-Won, et al.
Publicado: (2023)

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
por: Makri, Evangelia, et al.
Publicado: (2016)

Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management
por: Chrysavgis, Lampros, et al.
Publicado: (2020)

Sarcopenia as a Novel Risk Factor for Nonalcoholic Fatty Liver Disease
por: Noh, Junghyun
Publicado: (2020)

Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try
por: Ren, Tian-Yi, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease – a growing public health problem
por: Mikolašević, Ivana, et al.
Publicado: (2021)

The role of magnetic resonance elastography in the evaluation of nonalcoholic fatty liver disease
por: Idilman, Ilkay S., et al.
Publicado: (2023)

Sarcopenic Obesity, the Possible Culprit for Nonalcoholic Fatty Liver Disease or Fibrosis
por: Kang, Seong Hee, et al.
Publicado: (2023)

Clustering NAFLD: phenotypes of nonalcoholic fatty liver disease and their differing trajectories
por: Kantartzis, Konstantinos, et al.
Publicado: (2023)

Aerobic and Resistance Exercise: Synergistic Influence for Nonalcoholic Fatty Liver Disease
por: Chun, Ho Soo
Publicado: (2023)

Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
por: Yoon, Eileen Laurel, et al.
Publicado: (2023)

Elevated serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease
por: Jang, Byoung Kuk
Publicado: (2012)

Nonalcoholic fatty liver disease: One more reason to strengthen public health
por: Alaama, Tareef
Publicado: (2018)

A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease
por: Hwang, Seonghwan, et al.
Publicado: (2022)

Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
por: Chun, Ho Soo, et al.
Publicado: (2023)

Hepatic inflammation: an important target for biomarker development in nonalcoholic fatty liver disease
por: Khan, Hiba, et al.
Publicado: (2023)

Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?
por: Han, Eugene, et al.
Publicado: (2023)

Synergistic Preventive Effect of Aerobic and Resistance Exercises on Nonalcoholic Fatty Liver Disease
por: Cho, Ju-Yeon, et al.
Publicado: (2023)

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
por: Vairetti, Mariapia, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease
por: Bebawi, Emmanuel, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease Is a Stepping Stone in the Path toward Diabetes Mellitus
por: Heo, Nae-Yun
Publicado: (2019)

What are the key points in the association between the gut microbiome and nonalcoholic fatty liver disease?
por: Vallianou, Natalia, et al.
Publicado: (2019)

Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?
por: Cho, Yong Kyun
Publicado: (2018)

Vitamin A in Nonalcoholic Fatty Liver Disease: A Key Player in an Offside Position?
por: Berasain, Carmen, et al.
Publicado: (2020)

Serum Resistin as a Biomarker in Nonalcoholic Fatty Liver Disease: Is This a Road to be Taken?
por: Patoulias, Dimitrios
Publicado: (2021)

Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?
por: Jin, Qian, et al.
Publicado: (2022)

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
por: Yeh, Ming-Lun, et al.
Publicado: (2023)

It’s Ready for Targeting Muscle in Nonalcoholic Fatty Liver in This Era of Aging
por: Joo, Sae Kyung, et al.
Publicado: (2019)

Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease
por: Kontana, Anastasia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2pj2apusffrm20jej89l6lr7ph